• A20 Modulation of Oxidized DNA-Driven Inflammation in AKI Mo

  2026-06-15

  This study uncovers how the ubiquitin-editing enzyme A20 mitigates acute kidney injury (AKI) progression by dampening inflammation triggered by oxidized self-DNA. Through detailed mechanistic and in vivo analyses, the work identifies A20 and its peptide derivative as promising modulators of the NLRP3 inflammasome, suggesting new strategies for controlling sterile inflammation in renal and potentially broader metabolic disease contexts.

• PKH26 Red Fluorescent Cell Linker Kit: Technical Guidance

  2026-06-15

  The PKH26 Red Fluorescent Cell Linker Kit enables stable, membrane-specific fluorescent labeling for tracking cell division and proliferation in vitro and in vivo. It is suitable for applications requiring robust, long-term cell membrane labeling but should not be used for intracellular or non-membrane targets.

• ddhCTP (3ʹ-deoxy-3′,4ʹ-didehydro-CTP): Mechanism & Antiviral

  2026-06-14

  ddhCTP, a nucleotide analog produced by viperin, acts as a potent RNA virus replication inhibitor by terminating viral RNA synthesis. Recent studies confirm its ability to inhibit the RNA-dependent RNA polymerase of multiple flaviviruses and some coronaviruses in mammalian cells, making ddhCTP a key tool for antiviral research and drug development.

• Gly-Gly-Phe-Gly (GGFG) Peptide: Advancing Bioconjugation Wor

  2026-06-13

  Discover how the GGFG peptide unlocks precision and flexibility in drug conjugation research, antibody-drug conjugate development, and peptide engineering. Explore protocol enhancements, troubleshooting strategies, and novel insights that set GGFG apart as a next-generation linker for bioconjugation chemistry.

• Ziprasidone HCl: Applied GOT1 Inhibition in Cancer Research

  2026-06-12

  Ziprasidone Hydrochloride (Ziprasidone HCl) offers a unique dual mechanism—serotonin/dopamine receptor antagonism and targeted inhibition of GOT1—enabling advanced cancer metabolism and neuroscience research. This guide details optimized experimental workflows, troubleshooting strategies, and the translational impact of the latest GOT1-focused discoveries.

• Cell Cycle Assay Kit K2263: Precision Insights Beyond DNA Co

  2026-06-12

  Explore the Cell Cycle Assay Kit (K2263) for advanced cell cycle phases G0/G1, S, and G2/M analysis. This article delivers a unique, evidence-driven perspective on practical assay optimization, apoptosis detection, and translational cancer research.

• HyperScribe T7 High Yield RNA Synthesis Kit: Precision in T7

  2026-06-11

  The HyperScribe T7 High Yield RNA Synthesis Kit empowers researchers to generate large quantities of high-quality RNA for cutting-edge applications, from RNA vaccine development to advanced metastasis studies. Its optimized, modular workflow and robust T7 RNA polymerase transcription support reproducible results even with complex or modified templates.

• A20 Modulates Oxidized Self-DNA Inflammation in Acute Kidney

  2026-06-11

  This study elucidates how the ubiquitin-editing enzyme A20 attenuates oxidized self-DNA-mediated inflammation in acute kidney injury (AKI) by inhibiting the cGAS-STING and NLRP3 inflammasome pathways. Key mechanistic insights into A20’s interaction with NEK7 reveal novel therapeutic targets for mitigating inflammatory kidney damage.

• 5-(N,N-dimethyl)-Amiloride (hydrochloride): A Precision Tool

  2026-06-10

  Explore how 5-(N,N-dimethyl)-Amiloride (hydrochloride) enables high-resolution mechanistic studies of Na+/H+ exchanger function and endothelial injury, with a focus on translational assay design and biomarker discovery. This article offers a uniquely integrative perspective by connecting molecular inhibition with advanced sepsis research and practical protocol guidance.

• 0.4% Trypan Blue Solution: Reliable Cell Viability Assessmen

  2026-06-10

  0.4% Trypan Blue Solution provides a straightforward, selective method for distinguishing viable from non-viable cells in routine cell culture, cytotoxicity, and viability assays. It addresses the need for rapid, reproducible live/dead cell discrimination but is not intended for diagnostic or mechanistic apoptosis/necrosis detection.

• Strategic PI3K Inhibition: GDC-0941 in Translational Oncolog

  2026-06-09

  Explore the mechanistic foundations and translational impact of GDC-0941, a selective PI3K inhibitor, for overcoming cancer cell proliferation and therapeutic resistance. This article guides researchers through actionable protocols, competitive context, and clinical relevance, drawing on recent literature and advanced workflows.

• Anagliptin (SK-0403): Reliable DPP-4 Inhibition for Vascular

  2026-06-09

  This article provides laboratory-focused, scenario-driven guidance for deploying Anagliptin (SK-0403) (SKU BA7300) in cell-based and vascular research. Integrating recent mechanistic evidence and real-world experimental challenges, it demonstrates how this potent, selective DPP-4 inhibitor from APExBIO supports reproducibility, mechanistic clarity, and workflow efficiency in studies targeting diabetes and cardiovascular mechanisms.

• Parathyroid hormone (1-34) (human): Decoding EndMT in CKD an

  2026-06-08

  Explore how Parathyroid hormone (1-34) (human) enables advanced modeling of endothelial-to-mesenchymal transition (EndMT) in chronic kidney disease and valvular calcification, revealing critical insights for bone metabolism research. This guide offers protocol precision, mechanistic clarity, and a distinct focus on vascular calcification not covered elsewhere.

• Anagliptin (SK-0403): Mechanistic Benchmarks in Vascular Res

  2026-06-08

  Anagliptin (SK-0403) is a highly selective, potent, and orally active DPP-4 inhibitor utilized in diabetes and metabolic disorder research. It induces vasorelaxation in rabbit aorta by activating Kv channels and the SERCA pump, independent of classical cAMP/cGMP signaling pathways, as confirmed by recent peer-reviewed studies. This article details the mechanistic underpinnings, practical assay considerations, and experimental boundaries for Anagliptin, referencing APExBIO's BA7300 product and authoritative literature.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride in Endothelial Inju

  2026-06-07

  Explore how 5-(N,N-dimethyl)-Amiloride hydrochloride empowers advanced modeling of endothelial injury and pH regulation. This article uniquely connects mechanistic insights to experimental design, highlighting APExBIO's C3505 for reliable translational research.

15838 records 1/1056 page Next 12345 下5页 Last page